Statin use and risk for ovarian cancer: a Danish nationwide case-control study.
BACKGROUND
Limited data suggest that statin use reduces the risk for ovarian cancer.


METHODS
Using Danish nationwide registries, we identified 4103 cases of epithelial ovarian cancer during 2000-2011 and age-matched them to 58,706 risk-set sampled controls. Conditional logistic regression was used to estimate adjusted odds ratios (ORs) and 95% confidence intervals (CIs) for epithelial ovarian cancer overall, and for histological types, associated with statin use.


RESULTS
We observed a neutral association between ever use of statins and epithelial ovarian cancer risk (OR=0.98, 95% CI=0.87-1.10), and no apparent risk variation according to duration, intensity or type of statin use. Decreased ORs associated with statin use were seen for mucinous ovarian cancer (ever statin use: OR=0.63, 95% CI=0.39-1.00).


CONCLUSIONS
Statin use was not associated with overall risk for epithelial ovarian cancer. The inverse association between statin use and mucinous tumours merits further investigation.
Danish Cancer Society Research Centre, Danish Cancer Society, Strandboulevarden 49, Copenhagen DK-2100, Denmark.
L
L
Baandrup
Danish Cancer Society Research Centre, Danish Cancer Society, Strandboulevarden 49, Copenhagen DK-2100, Denmark.
C
C
Dehlendorff
Danish Cancer Society Research Centre, Danish Cancer Society, Strandboulevarden 49, Copenhagen DK-2100, Denmark.
S
S
Friis
Danish Cancer Society Research Centre, Danish Cancer Society, Strandboulevarden 49, Copenhagen DK-2100, Denmark.
J H
JH
Olsen
1] Danish Cancer Society Research Centre, Danish Cancer Society, Strandboulevarden 49, Copenhagen DK-2100, Denmark [2] The Gynaecologic Clinic, Juliane Marie Centre, Rigshospitalet, University of Copenhagen, Copenhagen, Denmark.
S K
SK
Kjær
D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D016022:Case-Control Studies; D003718:Denmark / Q000453:epidemiology; D005260:Female; D006801:Humans; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors / Q000008:administration & dosage*; D008875:Middle Aged; D010051:Ovarian Neoplasms / Q000453:epidemiology*; D012042:Registries; D012306:Risk
D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors